rareLife solutions

Name

rareLife solutions

Legal name

rareLife solutions

Website

https://rarelifesolutions.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Norwalk

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Medical Publications Services: Full-service scientific communications agency providing strategy, community building, scientific scaffold, content development, events, and internal training services to pharmaceutical and biotech clients developing rare disease therapies. Revenue generated through project-based and retainer engagements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

rareLife solutions is a first-of-its-kind full-service rare scientific agency providing medical publications and scientific communications services for pharmaceutical and biotech companies developing therapies for rare diseases. The agency operates across six service categories — Strategy, Community Building, Scientific Scaffold, Content Development, Events, and Internal Training — covering 65+ rare indications. The company also develops mApIt, a standalone AI-powered application for medical publications insights.

Product overview

rareLife solutions operates as a full-service rare scientific agency offering a broad suite of medical communications and scientific publications services structured into six categories: Strategy, Community Building, Scientific Scaffold, Content Development, Events, and Internal Training. The company also offers mApIt, an AI-powered standalone application for strategic medical publications insights. The service portfolio and the AI tool are designed to work together—services provide the human expertise and strategic framework while mApIt accelerates the identification of relevant insights from the rare disease publication landscape.

Differentiator

Problem solved

Functional benefit

Brands

• mApIt: AI-Powered Strategic Medical Publications Insights Tool - a cutting-edge, standalone, AI-powered application developed by medical publications experts to streamline the identification of relevant insights and support strategic publication planning for rare disease therapies in development.

Products and services

• mApIt (Medical Publications Insights Tool)
• Rare Scientific Agency Services

Quantifiable outcome

• Replaces months of manual effort with minutes of AI-powered analysis

Named customers11 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature1 record

Partnerships

Twelve partnerships are on record, tiered major and core.

• PfizermajorStrategic or Co-development PartnerPharmaceutical client partner for rare disease drug development and commercialization services including medical publications and scientific communications.
• AstraZenecamajorStrategic or Co-development PartnerPharmaceutical client partner for rare disease drug development and commercialization services.
• Alexion (AstraZeneca)majorStrategic or Co-development PartnerSubsidiary of AstraZeneca focused on rare diseases, serving as client for medical publications and scientific communications services.
• UCBmajorStrategic or Co-development PartnerPharmaceutical client partner for rare disease drug development and commercialization services.
• SOBI (Swedish Orphan Biovitrum)majorStrategic or Co-development PartnerPharmaceutical client partner specializing in rare diseases, receiving medical publications and scientific communications support.
• RegeneronmajorStrategic or Co-development PartnerPharmaceutical client partner for rare disease drug development and commercialization services.
• Orchard TherapeuticsmajorStrategic or Co-development PartnerBiotech client partner focused on rare diseases, receiving medical publications and scientific communications services.
• ExelixismajorStrategic or Co-development PartnerPharmaceutical client partner for rare disease drug development and commercialization services.
• UMDF (United Mitochondrial Disease Foundation)coreStrategic or Co-development PartnerNonprofit partner in the rare disease ecosystem, collaborating on community building and rare disease awareness initiatives.
• NORD (National Organization for Rare Disorders)coreStrategic or Co-development PartnerLeading nonprofit rare disease advocacy organization serving as ecosystem partner for rare disease awareness and patient community initiatives.
• CenteredcoreStrategic or Co-development PartnerNonprofit partner organization in the rare disease ecosystem, collaborating on community building and patient advocacy initiatives.
• Connecticut Rare Disease Advisory CouncilcoreStrategic or Co-development PartnerState-level advisory council focused on rare disease awareness. A rareLife team member serves on the council's Awareness Committee, contributing to policy shaping and amplifying rare community voices locally.

Scale indicators1 record

Recent moves5 records

Expansion highlights5 records

Direct peers

• Oxford PharmaGenesis: Independent medical communications agency with a recognized rare disease practice and deep publications expertise; closely mirrors rareLife's boutique model and pharma/biotech client base.
• OPEN Health: Global medical communications and HEOR group with explicit rare disease and oncology offerings spanning publications, HEOR, and patient engagement; competes for the same pharma accounts as rareLife.
• Nucleus Global: Network of medical communications agencies providing scientific publications and content development to pharma, including rare disease programs; comparable service mix and client overlap with rareLife.
• Fishawack Health: Global medical communications group (including CMC Connect and other agencies) with strong rare disease and specialty therapeutics practices serving top-20 pharma; a key competitive comparable for rareLife.
• Trilogy Writing & Consulting: Boutique medical writing and scientific communications consultancy serving pharma and biotech, including rare disease; similar size and specialty positioning to rareLife.
• The Lockwood Group: Medical communications and publications agency serving pharma clients across multiple therapeutic areas; comparable boutique-scale services provider to rareLife.
• Complete HealthVizion (IPG Health): Medical communications agency within IPG Health network providing scientific publications and content services to pharma, including rare disease programs.
• Ashfield MedComms (Inizio): Medical communications arm of Inizio, providing publications and scientific content services to pharma clients across therapeutic areas including rare disease.

Broad incumbents

• IQVIA Medical Communications: Largest life sciences services platform; its medical communications practice serves pharma clients including rare disease, offering a much broader portfolio (RWE, HEOR, consulting) than rareLife.
• Syneos Health Communications: Large CRO and commercialization services platform with a medical communications group serving pharma/biotech including rare disease; a broad incumbent competing for the same enterprise accounts.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/rareLifetalk
• LinkedInlinkedin.com/company/rarelife-solutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about rareLife solutions